WCN26-3100 Metabolic Impact of Sacubitril/Valsartan in Diabetic Hemodialysis Patients: Improved Glycoalbumin Without Altering Antidiabetic Therapy

Read full text Summarise with VIRAT
Authors: Minako Sakai, Jyunichiro Hashiguchi, Kenji Sawase, Akihiro Maekawa, Koutaro Shimoyama
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Sacubitril/valsartan (angiotensin receptor–neprilysin inhibitor; ARNI) is widely recognized for its cardioprotective and antihypertensive properties. Beyond these effects, neprilysin inhibition may preserve incretin-related peptides, such as GLP-1, thereby enhancing insulin sensitivity. However, its metabolic effects in maintenance hemodialysis (HD) patients have not been systematically investigated. In this population, glycoalbumin (GA) serves as a more accurate glycemic marker than HbA1c due to altered erythrocyte lifespan.

Fields of Study & Subjects

Dialysis and Renal Disease Management Chronic Kidney Disease and Diabetes Diabetes Treatment and Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104726–104726
Publication date
25 March 2026
Language
EN